PREVIEW
OF YOUR NEWS WIDGETHepatitis news and hepatitis widget
Monday, November 17, 2008 ( change date )
Hepatitis C Therapeutic DNA Vaccine Delivered By Inovio Biomedical's Electroporation Technology Reduces Viral Load By Up To 99.7%
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported positive additional interim results from its ongoing phase I/II clinical study of its therapeutic DNA vaccine against hepatitis C virus (HCV). This vaccine is being delivered using Inovio's electroporation-based DNA delivery system.
Medicalnewstoday.com Monday, November 17, 2008
INSTALL YOUR WIDGET